Register for OBR daily


To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

GERN $3.59 0.3399 +10.46%
GALE $2.01 0.1500 +8.06%
ARRY $3.84 0.1300 +3.50%
IMGN $10.01 0.3300 +3.41%
ARWR $5.92 0.1790 +3.12%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

NWBO $4.98 -0.2300 -4.41%
CPXX $2.00 -0.0850 -4.08%
PGNX $6.37 -0.1700 -2.60%
BPTH $2.83 -0.0700 -2.41%
MDVN $108.66 -2.5900 -2.33%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Next > | Last >>

Researchers Identify Biological Indicator of Response to New Ovarian Cancer Drug

(ECCO) Nov 20, 2014 - Researchers have found a way of identifying which ovarian cancer patients are likely to respond well to a new anti-cancer drug called rucaparib.
read press release 

Memorial Sloan Kettering Team Makes Key Discovery in Understanding Immunotherapy’s Successes—And Its Failures

(MSKCC) Nov 19, 2014 - A collaborative team of leaders in the field of cancer immunology from Memorial Sloan Kettering Cancer Center has made a key discovery that advances the understanding of why some patients respond to ipilimumab, an immunotherapy drug, while others do not.
read press release 

Breast Removal Rates Increasing For Early Cancers in U.S.

(Reuters Health) Nov 19, 2014 - More women in the U.S. are choosing to have their breasts removed for early cancers instead of breast-conserving procedures that deliver equal results, according to a new study.
read article 

Revised Medicare Payments Vex Surgery Groups

(MedPage Today) Nov 18, 2014 - Among the myriad of Medicare physician payment regulations issued late last month by the Centers for Medicare and Medicaid Services (CMS), there's one that has surgeons' groups very concerned: a rule changing 10- and 90-day global payments to zero-day payments.
read article (free registration required) 

Europe Approves Gilead HCV Combo Harvoni

(PharmaTimes [UK]) Nov 19, 2014 - Gilead Sciences has been boosted by the news that European regulators have given the green light to its hepatitis C combination treatment Harvoni.
read article 

Deal by Cystic Fibrosis Foundation Raises Cash and Some Concern

(New York Times) Nov 19, 2014 - The foundation is to announce that it will receive $3.3 billion after it helped finance the development of drugs for the deadly lung disease.
read article 

Sticker Shock: Some Medicare Part D Beneficiaries Will Pay More Next Year

(Wall Street Journal/Pharmalot blog) Nov 19, 2014 - More Part D beneficiaries will be expected to pay co-insurance, which means they will be asked to pay a higher percentage of the total cost of their medicines.
read article (paid subscription required) 

Anthem, Blue Shield Faulted for Doctor Lists

(Sacramento Bee) Nov 18, 2014 - California regulators determined that Anthem Blue Cross and Blue Shield of California violated state law and significantly exaggerated the number of doctors available and accepting patients under Covered California, the state’s year-old health insurance exchange.
read article 

Seeking the Right to Try

(U.S. News & World Report) Nov 18, 2014 - Laws allowing terminal patients to try drugs not approved by the FDA have passed in five states, but experts question their efficacy.
read article 

Improved Outcomes in Non-Small Cell Lung Cancer Due to Advancements in Screening, Diagnosis, Radiology, and Systemic Therapies

(NCCN) Nov 19, 2014 - The National Comprehensive Cancer Network® (NCCN®) has published the 20th annual edition of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer (NSCLC), one of the eight original NCCN Guidelines® published in November 1996.
read press release 

ASCO Takes Part in IOM Workshop on Molecularly Targeted Therapies for Cancer

(ASCO in Action) Nov 18, 2014 - ASCO Chief Medical Officer Richard L. Schilsky, MD, FACP, FASCO, served on the planning committee for a workshop sponsored by the National Cancer Policy Forum of the Institute of Medicine (IOM) on “Policy Issues in the Development and Adoption of Molecularly Targeted Therapies for Cancer.”
read article 

7 Takeaways From the ACCC National Oncology Conference

(Medscape Oncology) Nov 18, 2014 - In San Diego, October 8-10, 2014, the Association of Community Cancer Centers (ACCC) held the 31st annual National Oncology Conference. ACCC has been active for 40 years and has played a major role in helping hospital and physician cancer programs improve their cancer delivery services.
read article (free registration required) 

Merrimack Pharmaceuticals Receives FDA Fast Track Designation for MM-398 in Post-Gemcitabine Metastatic Pancreatic Cancer

(CNNMoney) Nov 19, 2014 - Merrimack Pharmaceuticals, Inc. announced today that the FDA has granted MM-398 (nanoliposomal irinotecan injection), also known as ''nal-IRI,'' Fast Track designation for the treatment of patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy.
read article 

TapImmune Announces Phase II Clinical Trials Collaboration With VGTI Florida to Advance Breast and Ovarian Cancer Vaccines

(TapImmune) Nov 18, 2014 - TapImmune, Inc., is pleased to announce a new collaborative research agreement with The Vaccine & Gene Therapy Institute of Florida (VGTI Florida), a leading, non-profit biomedical research institute, forming a partnership to advance TapImmune's proprietary, cancer vaccines into Phase II human clinical trials for the treatment of breast and ovarian cancers.
read corporate press release 

December 11, 2014: Pediatric Oncologic Subcommittee of the Oncologic Drugs Advisory Committee Meeting Announcement

( Dec 11, 2014 - Information will be presented to gauge investigator interest in exploring potential pediatric development plans for three products in various stages of development for adult cancer indications. The products under consideration are: (1) GANETESPIB, application submitted by Synta Pharmaceuticals Corp. (2) Etirinotecan, application submitted by Nektar Therapeutics, and (3) RO5503781, application submitted by Hoffmann-La Roche, Inc.
read article 

Foundation Medicine Winning Increased Insurance Coverage for Genetic Cancer Tests

(TheStreet) Nov 19, 2014 - Coverage decisions are still likely to slowly build over time but it is a clear positive that we are seeing the early adopters start to reimburse for Foundation's cancer tests.
read article 

SOTIO Initiates US part of VIABLE, a Global Phase III Clinical Trial for Prostate Cancer Immunotherapy Treatment with DCVAC/PCa

(Yahoo! News) Nov 19, 2014 - SOTIO, a biotechnology company owned by the PPF Group, today announced that the first US patient has been enrolled in its VIABLE study, the global Phase III clinical trial for DCVAC/PCa, an active cellular immunotherapy treatment for prostate cancer patients.
read article 

Genes and Sun Behaviors During Childhood May Play Large Role in Future Melanoma Risk

(AACR) Nov 19, 2014 - A longitudinal study established a link between different ultraviolet (UV) exposure measures in children, such as the number of waterside vacations or sunburns, and biomarkers of melanoma risk, such as the number of freckles or moles that develop during childhood, according to data published in Cancer Epidemiology, Biomarkers & Prevention.
read press release 

Common Blood Pressure Medication Does Not Increase Risk of Breast Cancer, Intermountain Medical Center Heart Institute Study Finds

(Intermountain Medical Center) Nov 19, 2014 - Women who take a common type of medication to control their blood pressure are not at increased risk of developing breast cancer due to the drug, according to new study by researchers at the Intermountain Medical Center Heart Institute in Murray, Utah.
read press release 

Men Who 'Monitor' Their Prostate Cancers Have High Quality of Life

(Reuters Health) Nov 18, 2014 – Men who decide with their doctors to keep a close eye on their prostate cancer - instead of treating it right away - tend to have physical and mental wellbeing equal to or better than men who opt for immediate treatment, suggests a new analysis.
read article 

Potential Therapy Found for Incurable Pediatric Brain Tumor

(Northwestern Medicine) Nov 17, 2014 - Northwestern Medicine scientists have discovered a new potential drug therapy for a rare, incurable pediatric brain tumor by targeting a genetic mutation found in children with the cancer.
read article 

ctDNA 'Liquid Biopsy' Could Revolutionize Cancer Care

(Medscape Medical News) Nov 18, 2014 - Faster than imaging, easier than tissue biopsy, the so-called "liquid biopsy" measures levels of circulating cell-free tumor DNA in blood.
read article (free registration required) 

Mirna Therapeutics Presents Interim Phase 1 Data on First-in-Class microRNA-34 mimic, MRX34, at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

(Yahoo! Finance) Nov 19, 2014 - Mirna Therapeutics today announced interim safety and preliminary efficacy data from a multicenter, open-label Phase 1 clinical trial of MRX34.
read article 

BIND Therapeutics Presents Positive Phase 2 Results Highlighting Potential of BIND-014 as Novel Anti-Cancer Treatment at Q3W Dosing Schedule for Patients with Non-small Cell Lung Cancer at 26th EORTC-NCI-AACR Annual Symposium

(CNBC) Nov 19, 2014 - BIND Therapeutics, Inc. today presented positive results from its ongoing Phase 2 study of BIND-014 in non-small cell lung cancer (NSCLC), demonstrating it has met the primary objective in the once every three weeks (Q3W) arm as measured by overall response rate (ORR).
read article 

Galeterone Shows Activity in a Variant Form of Castration-resistant Prostate Cancer

(ECCO) Nov 19, 2014 - Results from a trial of the anti-cancer drug galeterone show that it is successful in lowering prostate-specific antigen (PSA) levels in men with a form of prostate cancer that is resistant to treatment with hormone therapy (castration-resistant prostate cancer or CRPC).
read press release